Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 106, Issue 3, 2008, Pages 389-391

  Lehrer, Steven ^a   Montazem, André ^a   Ramanathan, Lakshmi ^a   Pessin Minsley, Melissa ^a   Pfail, John ^a   Stock, Richard G ^a   Kogan, Rita ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYERGOCALCIFEROL; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; OSTEOCALCIN; PARATHYROID HORMONE; PEPTIDE;

ARTICLE; BLOOD; BONE NECROSIS; BONE TUMOR; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; JAW DISEASE; MALE; POSTMENOPAUSE OSTEOPOROSIS; PROSTATE TUMOR;

25-HYDROXYVITAMIN D 2; ALKALINE PHOSPHATASE; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; HUMANS; JAW DISEASES; MALE; OSTEOCALCIN; OSTEONECROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PEPTIDES; PROSTATIC NEOPLASMS;

EID: 49049105446     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2008.01.033     Document Type: Article

References (11)

1. Wilkinson G.S., Kuo Y.F., Freeman J.L., and Goodwin J.S. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 99 (2007) 1016-1024
2. Durie B.G., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353 (2005) 99-102
3. Bamias A., Kastritis E., Bamia C., Moulopoulos L.A., Melakopoulos I., Bozas G., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 (2005) 8580-8587
4. Marx R.E., Sawatari Y., Fortin M., and Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567-1575
5. Migliorati C.A., Schubert M.M., Peterson D.E., and Seneda L.M. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104 (2005) 83-93
6. Coleman R.E., Major P., Lipton A., Brown J.E., Lee K.A., Smith M., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23 (2005) 4925-4935
7. Khosla S., and Melton III L.J. Clinical practice. Osteopenia. N Engl J Med 356 (2007) 2293-2300
8. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. Anonymous. J Oral Maxillofac Surg 65 (2007) 369-376
9. Colwell Jr. C.W., Robinson C.A., Stevenson D.D., Vint V.C., and Morris B.A. Osteonecrosis of the femoral head in patients with inflammatory arthritis or asthma receiving corticosteroid therapy. Orthopedics 19 (1996) 941-946
10. Mirzai R., Chang C., Greenspan A., and Gershwin M.E. The pathogenesis of osteonecrosis and the relationships to corticosteroids. J Asthma 36 (1999) 77-95
11. Ardine M., Generali D., Donadio M., Bonardi S., Scoletta M., Vandone A.M., et al. Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?. Ann Oncol 17 (2006) 1336-1337